Cencora (COR) Set to Announce Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is set to post its quarterly earnings results before the market opens on Wednesday, July 31st. Analysts expect Cencora to post earnings of $3.19 per share for the quarter. Cencora has set its FY24 guidance at $13.30-13.50 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping the consensus estimate of $3.65 by $0.15. The business had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.50 earnings per share. On average, analysts expect Cencora to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Cencora Stock Down 0.2 %

Shares of NYSE COR opened at $227.18 on Tuesday. The stock has a market cap of $45.31 billion, a P/E ratio of 24.86, a PEG ratio of 1.58 and a beta of 0.45. The business’s fifty day simple moving average is $227.08 and its 200-day simple moving average is $230.76. Cencora has a 12-month low of $171.65 and a 12-month high of $246.75. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio is currently 22.32%.

Analysts Set New Price Targets

A number of research firms recently weighed in on COR. Citigroup upped their target price on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Robert W. Baird boosted their target price on shares of Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 9th. Finally, SVB Leerink reissued an “outperform” rating and issued a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $238.78.

Insider Buying and Selling at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of Cencora stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the sale, the insider now owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Dermot Mark Durcan bought 500 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was acquired at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the acquisition, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The disclosure for this purchase can be found here. Insiders sold 1,899,112 shares of company stock worth $408,654,376 over the last 90 days. Corporate insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.